Ticagrelor (Brilinta)
Revision as of 12:52, 8 May 2021 by Jwarner (talk | contribs) (→History of changes in FDA indication)
General information
Class/mechanism: Reversible cyclopentyl-triazolo-pyrimidine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.
Route: PO
Extravasation: n/a
History of changes in FDA indication
Note that this agent does not have a hematology-specific indication at this time.
- 7/20/2011: Initial FDA approval to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction).
- 9/3/2015: Indication revised to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
Also known as
- Brand names: Brilinta, Brilique, Ticalog